Endocrine Abstracts

Background: Pituitary adenomas(PAs) comprise 10%–25% of all intracranial tumors, the majority of them being benign. But 35% of all PAs are considered invasive, having a higher recurrence rate than benign ones.Objectives: We analyzed the expression of different angiogenic growth factors and their receptors in PAs and identified correlations with the hormone profile that could explain their behavior and prognosis.Methods: Our st...

Introduction: Acromegaly is characterized by elevated levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), most often due to a pituitary tumor. Persistent high levels of these hormones lead to a constellation of signs and symptoms and systemic complications associated with increased mortality. A potential association between acromegaly and cancer has been hypothesized regarding colorectal, thyroid, and prostate cancers, but there are few or no descriptions f...

Background: The role of EGFR, HER2, PDGF-A and the axis PDGF-B/ PDGFR-β in the pathogenesis of pituitary adenomas and their correlation with the tumoral immunoprofile are poorly understood.Materials and methods: The study included 92 cases. We used morphological stains, immunohistochemistry and molecular methods to characterize the tumors.Results: 33.33% of adenomas showed a positive immunohistochemical reaction for HER2- with...

Introduction: Somatotroph pituitary adenomas (PAs) represent 10-15% of all resected PAs, exhibiting immunohistochemical (IHC) positivity for GH (growth hormone) and PIT-1 transcription factor (TF). The histopathological (HP) and IHC variability of each PA influences the phenotype, radiological features, and therapy response.Materials and methods: The study included 33 patients with acromegaly, with men: women ratio of 17:16. The HP-IHC characteristics we...

Introduction: Pituitary neuroendocrine tumors (PitNET) are characterized by a heterogenous behavior. The immunohistochemical (IHC) staining of anterior pituitary hormones, along with that of pituitary transcription factors and with the clinical and biochemical characteristics of the patients can be integrated in a risk stratification system, which helps the therapeutic management.Material and Methods: We analyzed 37 patients with confirmed diagnosis of a...

Introduction: Clinically non-functioning pituitary neuroendocrine tumours (NFPitNETs) include all anterior pituitary tumours that are not hormonally active. In histopathology (HP) and immunohistochemistry (IHC), most of NFPitNETs are gonadotroph (1). Immunolabeling is negative in only 10% of cases (‘null-cell’). Occasionally, NFPitNETs are positive for GH, PRL, TSH or ACTH despite absent or only minimal secretion of these hormones in vivo, which are known as...